Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis

Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis

Atherosclerosis is the major cause of cardiovascular disease. This study evaluated the effect of lipid lowering using a novel peptide inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and a monoclonal antibody against angiopoietin-like 3 (evinacumab), either alone or in combination in...

Full description

Saved in:
Bibliographic Details
Main Authors: José A. Inia, Anita van Nieuwkoop-van Straalen, J. Wouter Jukema, Bidda Rolin, Ellen Marie Staarup, Christina K. Mogensen, Hans M.G. Princen, Anita M. van den Hoek
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Journal of Lipid Research
Subjects:
evinacumab
atherosclerosis
PCSK9
ANGPTL3
APOE∗3-Leiden.CETP mice
combination therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227525000136
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items